



Viral Epidemiology Snapshot: November 6-12, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	992	212	21.4%
Flu B	992	5	0.5%
RSV	612	244	39.9%
CoV-2 PUI	1072	61	5.7%
CoV-2 Surveillance	18	1	5.6%


Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	541	36	6.7%
Coronavirus 229E	541	0	0.0%
Coronavirus HKU1	541	0	0.0%
Coronavirus NL63	541	2	0.4%
Coronavirus OC43	541	1	0.2%
Metapneumovirus	541	9	1.7%
Rhinovirus/Enterovirus	541	159	29.4%
Parainfluenza 1	541	22	4.1%
Parainfluenza 2	541	1	0.2%
Parainfluenza 3	541	6	1.1%
Parainfluenza 4	541	14	2.6%

Flu A Subtyping

2009 H1N1	7
Seasonal H1	0
Seasonal H3	69
No Subtype	136
Pending subtype	0

Flu, RSV, & CoV-2 Trends




This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza and SARS-CoV-2 (as of 2/2020) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as “no subtype”.

Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line (“PUI”) shows data for all patients with symptoms or known exposures (“Patient Under Investigation”) while the purple line (“Surv.”) shows surveillance data for undergoing pre-procedure screening.

CoV-2 Positivity Rate Trends



As of 10/2021, the surveillance line shows patients who have been designated as “pre-procedure” in their testing order questionnaire, as well as participants in the employee screening program. In 9/2022 the employee screening program ended and pre-procedure screening was made at provider-discretion.